Encke Jens, Bernardin Jomo, Geib Jasmin, Barbakadze Gocha, Bujdoso Raymond, Stremmel Wolfgang
Gastroenterology, Hepatology, Infectious Diseases, Intoxications, Department of Internal Medicine IV, University of Heidelberg Medical School, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
World J Gastroenterol. 2006 Nov 28;12(44):7118-25. doi: 10.3748/wjg.v12.i44.7118.
To investigate whether transfection of plasmid DNA encoding these cytokines enhances both humoral and cellular immune responses to hepatitis C virus (HCV) in a murine model.
We established a tumor model of HCV infection using syngenic mouse myeloma cells stably transfected with NS5. Co-vaccination of DNA encoding granulocyte macrophage colony-stimulating factor (GM-CSF) and Flt-3 ligand together with a plasmid encoding for the HCV NS5 protein was carried out. Mice were sacrificed 14 d after the last immunization event with collection of spleen cells and serum to determine humoral and cellular immune responses.
Co-vaccination of DNA encoding GM-CSF and Flt-3 ligand together with a plasmid encoding for the HCV NS5 protein induced increased antibody responses and CD4+ T cell proliferation to this protein. Vaccination with DNA encoding GM-CSF and Flt-3L promoted protection against tumor formation and/or reduction in mice co-immunized with cytokine-encoding DNA constructs. This suggests this strategy is capable of generating cytotoxic T lymphocyte activity in vivo. Following inoculation with plasmid DNA encoding Flt-3L, no increase in spleen size or in dendritic cell (DC) and natural killer cell numbers was observed. This was in contrast to a dramatic increase of both cell types after administration of recombinant Flt3-L in vivo. This suggests that vaccination with plasmid DNA encoding cytokines that regulate DC generation and mobilization may not promote unwanted side effects, such as autoimmunity, splenic fibrosis or hematopoietic malignancies that may occur with administration of recombinant forms of these proteins.
Our data support the view that plasmid DNA vaccination is a promising approach for HCV immunization, and may provide a general adjuvant vaccination strategy against malignancies and other pathogens.
在小鼠模型中研究编码这些细胞因子的质粒DNA转染是否能增强对丙型肝炎病毒(HCV)的体液免疫和细胞免疫反应。
我们利用稳定转染NS5的同基因小鼠骨髓瘤细胞建立了HCV感染肿瘤模型。将编码粒细胞巨噬细胞集落刺激因子(GM-CSF)和Flt-3配体的DNA与编码HCV NS5蛋白的质粒一起进行联合疫苗接种。在最后一次免疫事件后14天处死小鼠,收集脾细胞和血清以确定体液免疫和细胞免疫反应。
将编码GM-CSF和Flt-3配体的DNA与编码HCV NS5蛋白的质粒一起进行联合疫苗接种可诱导针对该蛋白的抗体反应增加和CD4+T细胞增殖。用编码GM-CSF和Flt-3L的DNA进行疫苗接种可促进对与编码细胞因子的DNA构建体共同免疫的小鼠的肿瘤形成保护和/或肿瘤减少。这表明该策略能够在体内产生细胞毒性T淋巴细胞活性。接种编码Flt-3L的质粒DNA后,未观察到脾脏大小、树突状细胞(DC)和自然杀伤细胞数量增加。这与体内给予重组Flt3-L后这两种细胞类型的显著增加形成对比。这表明用编码调节DC生成和动员的细胞因子的质粒DNA进行疫苗接种可能不会促进与给予这些蛋白的重组形式相关的不良副作用,如自身免疫、脾纤维化或造血系统恶性肿瘤。
我们的数据支持以下观点,即质粒DNA疫苗接种是一种有前景的HCV免疫方法,并且可能提供一种针对恶性肿瘤和其他病原体的通用辅助疫苗接种策略。